Research programme: lysosome pathway modulators - Catabasis PharmaceuticalsAlternative Names: CAT 5000
Latest Information Update: 07 May 2013
At a glance
- Originator Catabasis Pharmaceuticals
- Mechanism of Action Glutathione synthase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 07 May 2013 Programme is still in early research in US
- 01 May 2013 Preclinical trials in Metabolic disorders in USA (unspecified route)
- 28 Sep 2011 Early research in Inflammation in USA (unspecified route)